Stocks · News reference
Bionano Genomics Says New York State Department Of Health Approved Optical Genome Mapping Lab Developed Tests At University Of Rochester Medicine For Genetic Disorders, Hematologic Malignancies
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bionano Genomics Stock Surges Tuesday: What's Going On?
Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.
Bionano Genomics Highlights Three New Independently Authored, Peer-Reviewed Publications Showing Clinical Utility Of OGM In High-Risk Hematologic Malignancies
Bionano Genomics, Inc. (NASDAQ:BNGO) today highlighted three new independently authored, peer-reviewed publications demonstrating the clinical utility of OGM in high-risk hematologic malignancies — myelodysplastic
8-K filing — Bionano Genomics, Inc. (BNGO)
Filed: 2026-09-14 AccNo: 0001411690-26-000046 Size: 13 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits